Tyrell J. Rivers, PhD, has served as a member of the Board of Directors of ADC Therapeutics since June 2018.
Dr. Rivers is also an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures, where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development.
Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers serves on the Board of Directors for Armaron Bio Ltd, Corvidia Therapeutics, PhaseBio Pharmaceuticals, Inc. and Viela Bio, Inc. and previously G1 Therapeutics, Inc. (GTHX). He also serves as a board observer for several private companies.